GSK rises on flu shot rollout, legal win in zantac lawsuits

GlaxoSmithKline (GSK) shares gained after it began shipping FDA-cleared flu vaccines Fluarix and Flulaval in the US. The rollout comes as the US recovers from its worst flu season in 15 years. In a boost for the stock, GSK also won a major legal battle as the Delaware Supreme Court dismissed expert evidence in the Zantac cancer lawsuits.